Cargando…

Efficacy and Safety of Triazavirin Therapy for Coronavirus Disease 2019: A Pilot Randomized Controlled Trial

No therapeutics have been proven effective yet for the treatment of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To assess the efficacy and safety of Triazavirin therapy for COVID-19, we conducted a randomized, double-blinded controlled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Xiaoke, Yu, Kaijiang, Wang, Yongchen, Xu, Wanhai, Ma, Hongli, Hou, Yan, Li, Yue, Cai, Benzhi, Zhu, Liying, Zhang, Min, Hu, Xiaoli, Gao, Jingshu, Wang, Yu, Qin, Huichao, Wang, Wenjie, Zhao, Mingyan, Wu, Xia, Zhang, Yong, Li, Lu, Li, Kang, Du, Zhimin, Mol, Ben Willem J., Yang, Baofeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company. 2020
Materias:	Research Coronavirus Disease 2019—Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476906/ https://www.ncbi.nlm.nih.gov/pubmed/32923016 http://dx.doi.org/10.1016/j.eng.2020.08.011

Ejemplares similares

The Efficacy and Safety of Triazavirin for COVID-19: A Trial Protocol
por: Wu, Xiaoke, et al.
Publicado: (2020)

A second functional furin site in the SARS-CoV-2 spike protein
por: Zhang, Yue, et al.
Publicado: (2022)

Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell–cell fusion, and neutralization sensitivity
por: Zhang, Li, et al.
Publicado: (2022)

Triazavirin—A Novel Effective Antiviral Drug
por: Chupakhin, Oleg N., et al.
Publicado: (2022)

Vaccination effects on post-infection outcomes in the Omicron BA.2 outbreak in Shanghai
por: Wu, Qianhui, et al.
Publicado: (2023)

Potential Treatment of COVID-19 with Traditional Chinese Medicine: What Herbs Can Help Win the Battle with SARS-CoV-2?
por: Li, Lin, et al.
Publicado: (2022)

Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector
por: Liang, Ziteng, et al.
Publicado: (2023)

Enlightenment from the COVID-19 Pandemic: The Roles of Environmental Factors in Future Public Health Emergency Response
por: Wang, Xiaolei, et al.
Publicado: (2022)

Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination
por: Wang, Meiyu, et al.
Publicado: (2021)

Aggravated pneumonia and diabetes in SARS-CoV-2 infected diabetic mice
por: Huang, Qing, et al.
Publicado: (2023)

Omicron infections profile and vaccination status among 1881 liver transplant recipients: a multi-centre retrospective cohort
por: Ma, Ensi, et al.
Publicado: (2022)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
por: Zhang, Li, et al.
Publicado: (2021)

Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1
por: Liu, Shuo, et al.
Publicado: (2023)

Single cell characteristics of patients with vaccine-related adverse reactions following inactivated COVID-19 vaccination
por: Jiang, Manling, et al.
Publicado: (2023)

Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation
por: Bei, Zhu-Chun, et al.
Publicado: (2023)

A Predictive Nomogram for Predicting Improved Clinical Outcome Probability in Patients with COVID-19 in Zhejiang Province, China
por: Xie, Jiaojiao, et al.
Publicado: (2022)

Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD
por: Li, Yulei, et al.
Publicado: (2023)

A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates
por: An, Yaling, et al.
Publicado: (2022)

Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice
por: Li, Xingxing, et al.
Publicado: (2022)

Etesevimab in combination with JS026 neutralizing SARS-CoV-2 and its variants
por: Wang, Fengze, et al.
Publicado: (2022)

Clinical Significance of the Correlation between Changes in the Major Intestinal Bacteria Species and COVID-19 Severity
por: Tang, Lingling, et al.
Publicado: (2020)

A case–case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variants
por: Wu, Dan, et al.
Publicado: (2022)

B cell receptor signatures associated with strong and poor SARS-CoV-2 vaccine responses
por: Lin, Ke, et al.
Publicado: (2022)

An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants
por: Shen, Yinzhong, et al.
Publicado: (2022)

Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial
por: Jin, Lairun, et al.
Publicado: (2022)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

Three doses of an inactivation-based COVID-19 vaccine induces cross-neutralizing immunity against the SARS CoV-2 Omicron variant
por: Yu, Xiaoling, et al.
Publicado: (2022)

Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants
por: Fan, Shengtao, et al.
Publicado: (2022)

Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern in real-world: a literature review and meta-analysis
por: Shao, Weihao, et al.
Publicado: (2022)

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study()
por: Cai, Qingxian, et al.
Publicado: (2020)

Shared IGHV1-69-encoded neutralizing antibodies contribute to the emergence of L452R substitution in SARS-CoV-2 variants
por: Yan, Qihong, et al.
Publicado: (2022)

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost
por: Ai, Jingwen, et al.
Publicado: (2022)

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
por: Xia, Shuai, et al.
Publicado: (2023)

Identification of TMEM53 as a novel SADS-CoV restriction factor that targets viral RNA-dependent RNA polymerase
por: Yao, Yu-Lin, et al.
Publicado: (2023)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

MERS-CoV nsp1 regulates autophagic flux via mTOR signalling and dysfunctional lysosomes
por: Feng, Yujie, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

RT-LAMP assay for rapid detection of the R203M mutation in SARS-CoV-2 Delta variant
por: Yang, Jianing, et al.
Publicado: (2022)

Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein
por: Xu, Shiqi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qsk1gv04nih6k75inrrpvt0fn8